Study find

Study finds rapid and broad immune response to third dose of BNT162b2 COVID-19 vaccine in individuals older than 60 years of age

A rapid and broad immune response to the third dose of BNT162b2 (Pfizer-BioNTech) coronavirus disease 2019 (COVID-19) vaccine was observed in individuals >60 years of age, according to a study published in the Journal of Infectious Diseases.  “In this real life study of adults older than 60 [years of age], we demonstrate that within one week after receiving the third dose of the BNT162b2 mRNA COVID-19 vaccine a significant response was observed in all participants, even those who did not respond to previous doses. More so, the response to the third dose was greater than the response to the ...

Effects of common weight loss plans on diabetes mellitus and cardiovascular risk factors

Diabetes mellitus is globally considered one of the most common chronic diseases, management of whic...

Study suggests patients on anti-CD20 treatment able to mount potent T-cell responses following ...

Patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA coronavirus diseas...


Suggested videos

Search:
Date
Filters:
Associatio
2:59

Associations of hypoglycaemia and glycaemic variability with cardiac arrhythmias using a long-term monitoring approach in insulin-treated patients with type 2 diabetes

Presenter: Andreas Andersen
Diabetology : Diabetes
EASD 2021
The role o
4:35

The role of SGLT2 inhibitors in the treatment of diabetes with cardiovascular disease

Presenter: Mikael Rydén
Diabetology : Diabetes
EASD 2021
The curren
14:50

The current issues in Hypoglycaemia

Presenter: Brian Frier
Diabetology : Diabetes
EASD 2021
Current gu
12:05

Current guidelines on diabetes management

Presenter: Christoph Wanner
Diabetology : Diabetes
EASD 2021
Spotlight
16:53

Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)

Presenter: Peter Galle
Oncology
ESMO 2021
The MONALE
8:37

The MONALEESA-2 trial

Presenter: Gabriel N. Hortobagyi
Oncology
ESMO 2021
Should Cur
16:32

Should Cure Be A Reasonable Goal in aRCC?

Presenter: David F. McDermott
Oncology
ESMO 2021
Is Unresec
6:32

Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?

Presenter: Alessandra Curioni-Fontecedro
Oncology
ESMO 2021
The Keynot
7:05

The Keynote 716 trial

Presenter: Jason J. Luke
Oncology
ESMO 2021
Navigating
5:56

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Judy King
Oncology
ESMO 2021
Metastases
7:04

Metastases-free survival results from STAMPEDE trial

Presenter: Gerhardt Attard
Oncology
ESMO 2021
Navigating
5:19

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Wolfgang Janni
Oncology
ESMO 2021
Highlights
10:39

Highlights of the ESMO 2021 Congress

Presenter: Solange Peters
Oncology
ESMO 2021
SSaSS: Sal
3:42

SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death

Presenter: Bruce Neal
Cardiology
ESC 2021
2021 ESC G
7:39

2021 ESC Guidelines - CVD Prevention

Presenter: Frank Visseren
Cardiology
ESC 2021
The digita
11:38

The digital age: The future of respiratory medicine

Presenter: Henry Chrystyn
Respiratory
ERS 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology
The role o
10:22

The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction

Presenter: Michael A. Nauck
Cardiology , Diabetology
Clinical I
9:00

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Alexander Miras
Cardiology , Diabetology